A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
Trial details
- Registry ID
- NCT06331299
- Phase
- Phase 3
The PDUFA goal date for UGN-103 (UGN-103 (mitomycin) for intravesical solution) in recurrent low-grade intermediate risk NMIBC is 14 Jun 2027, as disclosed by UroGen Pharma Ltd. (URGN).
Drug identity checked against registry records
Also recorded as UGN-103 (mitomycin) for intravesical solution
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder CancerNCT06331299 | URGN | Phase 3 | Completed | 2025-09-11Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2027-06-14Day | UGN-103UroGen Pharma Ltd. · URGN | Company-disclosed PDUFA goal dateAnnounced review target | recurrent low-grade intermediate risk NMIBC | Open original sourceRead source excerptIn August 2026, we submitted an NDA for UGN-103 for the treatment of adults with recurrent low-grade intermediate risk NMIBC supported by the clinical data from the ongoing Phase 3 UTOPIA trial, and in October 2026, we announced the FDA's acceptance of the NDA and the assignment of a Prescription Drug User Fee Act ("PDUFA") target action date of June 14, 2027. First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026 |
| 2027-06-14Day | UGN-103UroGen Pharma Ltd. · URGN | Company-disclosed PDUFA goal dateAnnounced review target | adults with recurrent low-grade intermediate risk NMIBC | Open original sourceRead source excerptOur NDA for UGN-103 for the treatment of adults with recurrent low-grade intermediate risk NMIBC is presently under review by FDA with a PDUFA target action date of June 14, 2027. First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026 |
| 2027-06-14Day | UGN-103UroGen Pharma Ltd. · URGN | Company-disclosed PDUFA goal dateAnnounced review target | recurrent LG-IR-NMIBC | Open original sourceRead source excerptIn October 2026, the FDA accepted for review UroGen’s NDA for UGN-103 and assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 14, 2027. The NDA is based on clinical data from the ongoing Phase 3 UTOPIA trial, a single-arm, multicenter trial evaluating the efficacy and safety of UGN-103 in adult patients with recurrent LG-IR-NMIBC. First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026 |